Market Assessment and Capacity Planning for Pancreatic Cancer CDMO Entry

A global Contract Development and Manufacturing Organization (CDMO) sought Stellarix’s support to assess the strategic and financial viability of pancreatic cancer-focused manufacturing devices. Our strategic intelligence enabled demand-driven capacity planning and informed market entry through effective risk mitigation and clear market visibility.

Client Background:

A global Contract Development and Manufacturing Organization (CDMO) intended to evaluate its entry into pancreatic cancer–focused manufacturing services, to support clinical and commercial supply for oncology programs.

Engagement Objective:

A market-driven assessment was conducted, combining secondary research with targeted primary interviews to support Go/No-Go and capacity planning decisions:

• Evaluated the pancreatic cancer therapy market and outsourced CDMO opportunity, including market size, growth, unmet needs, and pharma outsourcing inclination.
• Assessed demand-side drivers, identifying anchor customers, modality mix, geographic demand concentration, and 5-year volume outlook.
• Mapped current and future CDMO capacity, highlighting supply gaps across small molecules, biologics, ADCs, and emerging modalities.
• Conducted primary interviews with pharma, biotech, and CDMO experts to validate demand assumptions, capacity constraints, and partnership expectations.
• Developed a high-level capacity and investment framework, covering production scale, location considerations, and infrastructure requirements.

Client Impact:

• Informed Go / No-Go Decision – Enabled the client to evaluate market attractiveness, unmet needs, and competitive dynamics to make a data-backed entry decision.
• Clear Market Visibility – Delivered a robust view of pancreatic cancer market growth, outsourced CDMO wallet evolution, and demand concentration across key geographies.
• Demand-Driven Capacity Planning – Translated pipeline and customer insights into a phased capacity roadmap covering suites, lines, batch sizes, and cold-chain needs.
• Modality Strategy Alignment – Identified current and future modality trends (small molecules, biologics, ADCs, CGT) to guide technology and infrastructure investments.
• Risk Mitigation – Highlighted supply-side gaps, competitive capacity constraints, and operational risks to support prudent capital allocation.
• Accelerated Strategic Execution – Equipped leadership with integrated secondary + primary market intelligence to advance investment planning, site selection, and customer engagement strategy.

Outcome Snapshot: